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Abstract
We previously demonstrated statins to enhance cytokine-mediated nitric oxide (NO) synthesis in vascular smooth muscle cells (VSMC).
To clarify the mechanism by which this occurs, we evaluated the effects of fluvastatin in lipopolysaccharide (LPS)-stimulated VSMC. NO
production induced by LPS was dose-dependently enhanced by fluvastatin, as were iNOS mRNA levels and iNOS protein expression.
Exogenous mevalonate and geranylgeranylpyrophosphate (GGPP) dampened the stimulatory effect of fluvastatin. A pull-down assay
demonstrated fluvastatin to decrease levels of GTP-bound Rho A. Moreover, a Rho-kinase inhibitor, Y-27632, was observed to enhance LPS-
induced NO production. We recently demonstrated that disrupting F-actin formation dramatically potentiates the ability of LPS to induce
iNOS mRNA and protein expression. In the present study, staining of F-actin with nitrobenzoxadiazole (NBD)-phallacidin demonstrated that
fluvastatin significantly impairs F-actin stress fiber formation. In light of these results, the ability of statins to increase NO production is due,
at least in part, to their ability to block the biosynthesis of mevalonate, thereby preventing isoprenoid biosynthesis. This inhibits Rho/Rho-
kinase signalling and, in turn, disrupts the actin cytoskeleton. Further analysis of the signalling pathway by which the actin cytoskeleton
affects iNOS expression might yield new insight into mechanisms of regulation of NO production.
D 2004 Elsevier B.V. All rights reserved.
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1. Introduction
Immunostimulants trigger vascular smooth muscle cells
(VSMC) to express the inducible isoform of nitric oxide
synthase (iNOS) [1–3]. Induction of iNOS and overproduc-
tion of nitric oxide (NO) in VSMC have been implicated in
septic and cytokine-induced circulatory shock [4,5]. In
short, elucidating the mechanism by which iNOS activity
is controlled might lead to the development of therapeutic
agents which limit NO overproduction and its corollary
effects. Induction of iNOS leading to NO production by
VSMC has also been observed in specific pathological
conditions, such as atherosclerosis [6,7]. Although the
contribution of iNOS to atherosclerotic changes remains
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pression is valuable in the treatment or limitation of athero-
sclerosis [8–10].
Large clinical trials have shown that inhibition of choles-
terol biosynthesis by 3-hydroxy-3-methylglutaryl (HMG)-
CoA reductase inhibitors (statins) improves clinical out-
comes in patients with atherosclerosis [11,12]. Statins may
exert anti-atherosclerotic effects, beyond those achieved with
normalization of hypercholesterolemia alone, through their
direct actions on endothelial cells, macrophages and VSMC
[13–15]. Statins inhibit the synthesis of isoprenoid inter-
mediates, such as farnesylpyrophosphate (FPP) and geranyl-
geranylpyrophosphate (GGPP). Both FPP and GGPP are
required for the posttranscriptional modification of several
proteins, including small G proteins, such as Ras, and Rho
GTP-binding proteins [16,17]. We previously demonstrated
that statins enhance cytokine-mediated NO synthesis in
VSMC [18]. This effect of statins on NO production is due
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thereby inhibiting isoprenoid biosynthesis.
We recently observed disruption of F-actin formation by
sequestration of G-actin using the toxin latrunculin B (Lat
B) to dramatically potentiate lipopolysaccharide (LPS)-in-
duced enhancement of iNOS mRNA and protein expression
[19]. We also observed Lat B to enhance interleukin-1h- and
TNFa-induced NO production. This indicates that disrup-
tion of the actin cytoskeleton up-regulates cytokine-induced
iNOS expression. Statins may inhibit Rho/Rho-kinase sig-
nalling by preventing isoprenoid biosynthesis, thereby dis-
rupting the actin cytoskeleton. Thus, analysis of the
signalling which occurs between the actin cytoskeleton
and determinants of iNOS expression may yield new insight
into the mechanism by which statins up-regulate NO pro-
duction. The present study was performed to examine the
effects of fluvastatin on LPS-induced NO production in
VSMC.A
2. Materials and methods
2.1. Cell culture
VSMC were isolated by elastase and collagenase diges-
tion of thoracic aortae from male Wistar rats [20]. The
culture medium was replaced twice weekly with Dulbecco’s
modified minimal essential medium (DMEM) containing
10% fetal bovine serum and antibiotics (100 Ag/ml piper-
acillin and 100 Ag/ml streptomycin). Cells in passages 10 to
15 were used for the experiments.
The experimental protocol was in accordance with the
Guide for the Care and Use of Laboratory Animals, pub-
lished by the US National Institute of Health (NIH Publica-
tion No. 85-23, revised 1985).
2.2. Nitrite assay
Nitrite accumulation, an indicator of NO synthesis, was
measured in the cell culture medium of confluent VSMC
[21]. Nitrite was quantified by measuring absorbance after
adding 100 Al of Griess reagent (1% sulfanilamide and 0.1%
naphthylenediamine in 5% phosphoric acid) to 100-
Al samples. Absorbance at 550 nm was determined using
a microplate reader (Molecular Devices, Richmond, CA,
USA). Nitrite concentrations were calculated by comparison
with the absorbance readings of standard solutions of
sodium nitrite prepared in cell culture medium.
We examined the effect of Y-27632 and Lat B on nitrite
production in LPS-or LPS/IFN-stimulated VSMC in the
presence or absence of fluvastatin.
2.3. iNOS mRNA analysis
Standard Northern blotting was used to investigate iNOS
mRNA expression, as described previously [18]. The probe
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obtained by reverse transcription-polymerase chain reaction
(RT-PCR), using specific primers for iNOS [19] labeled
with [a-32P]dCTP by random priming.
2.4. Western blot of iNOS
Samples containing 10 Ag of protein were resolved by
electrophoresis on a 7% SDS-polyacrylamide gel, after
which the bands from each sample were transferred to a
PVD membrane (Bio-Rad) which was incubated with mouse
monoclonal IgG1 antibody against rat iNOS (1:800) (Wako
Pure Chemical Industries, Ltd., Osaka, Japan). The binding
of iNOS antibody was detected using sheep anti-mouse IgG
horseradish peroxidase (1:20000) and the ECL Plus system
(Amersham, Buckinghamshire, UK).
2.5. Determination of Rho activity
Rho A activity was determined by measuring GTP-Rho,
using the Rho-binding domain of rhotekin. Briefly, the cells
were treated with or without 25 AM fluvastatin, followed by
extraction with a lysis buffer (50 mmol/l Tris, pH 7.2, 500
mmol/l NaCl, 10 mmol/l MgCl2, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 20 Ag/ml antipain, 20 Ag/
ml leupeptin, and 1 Amol/l PMSF). After centrifugation at
12,000 g for 10 min at 4jC, the extract was incubated for
45 min at 4jC with glutathione-Sepharose 4B beads cou-
pled with glutathione-S-transferase (GST) rhotekin fusion
protein. The beads were then washed three times with a
washing buffer (50 mmol/l Tris, pH 7.2, 150 mmol/l NaCl,
10 mmol/l MgCl2, 1% Triton X-100, 20 Ag/ml antipain, 20
Ag/ml leupeptin, and 1 Amol/l PMSF) and boiled for 5 min
in a loading buffer. The amount of Bound Rho A protein
was quantitatively determined by Western blotting using a
mouse monoclonal antibody to Rho A at a dilution of 1:500
(Santa Cruz Biotechnology).
2.6. Fluorescence microscopy
VSMC grown on glass coverslips were either left untreat-
ed or were treated with 25 AM fluvastatin and/or LPS/IFN for
6 h. Actin within the cells was stained with nitrobenzox-
adiazole (NBD)-phallacidin (Molecular Probes). Cells
grown on the coverslips were washed twice with prewarmed
PBS, pH 7.4, and then fixed in 3.7% formaldehyde in PBS
for 10 min at room temperature. After the coverslips were
washed three times in phosphate buffer saline (PBS), they
were placed in glass petri dishes and permeabilized with
acetone at 20jC for 5 min. The cells were then washed twice
with PBS and stained with 165 nM NBD-phallacidin in PBS
for 20 min. To reduce nonspecific background staining, the
fixed cells were preincubated with PBS containing 1% BSA
for 20 min before the NBD-phallacidin solution was added.
The cells were washed three times with PBS before being
mounted on slides, which were placed cell side down in a 1:1
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using a Nikon epifluorescent microscope.
2.7. Statistical analysis
Data are presented as the meanF S.E. Statistical signif-
icance between more than two groups was tested by means
of two-way ANOVA followed by the Newman–Keuls testFig. 1. (A) Effect of fluvastatin on nitrite production in LPS- or LPS/IFN-
stimulated rat VSMC. Cells were incubated with LPS or a combination of
LPS and IFN in the absence (black bars) or presence (grey bars) of
fluvastatin (25 AM) for 24 h, after which nitrite accumulation in the medium
was measured. Inset: Cells were incubated with LPS in the presence of
various concentrations of fluvastatin for 24 h, after which nitrite
accumulation within the medium was measured. (B) Time course of nitrite
production in rat VSMC stimulated with LPS/IFN. Nitrite accumulation in
the culture medium was measured at the indicated times in the absence
(open circles) or presence of fluvastatin (closed circles). Data with regard to
nitrite accumulation are presented as the meanF S.E. (n = 6). *P< 0.05 and
**P < 0.01 compared with control values (no fluvastatin).
Fig. 2. Effect of fluvastatin on the induction of iNOS mRNA and iNOS
protein expression in LPS/IFN-stimulated VSMC. Cells were incubated
with LPS/IFN in the absence or presence of fluvastatin (25 AM) for 24 h.
Total RNA was isolated, and Northern hybridized with a rat iNOS-specific
probe. iNOS protein was detected by Western blotting as a band with a
molecular mass of f 125 kDa.
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or unpaired two-tailed Student’s t test as appropriate, and
values of P < 0.05 were considered to indicate statistical
significance.
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3. Results
LPS (30 Ag/ml) activates rat VSMC to synthesize and
release nitrite. LPS-induced nitrite release was markedly
CFig. 3. Effect of mevalonate and isoprenoids on the action of fluvastatin.
Cells stimulated with LPS/IFN (black bars) or LPS/IFN plus fluvastatin (25
AM, gray bars) were incubated in the presence of mevalonate (MV, 0.1
mM), FPP (10 AM), or GGPP (10 AM) for 24 h, after which nitrite
accumulation in the culture medium was measured. Basal: no LPS/IFN.
Data are presented as the meanF S.E. (n = 6). *P< 0.05 and **P < 0.01
compared with control values.
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VSMC treated with IFN alone (at concentrations of up to
1000 units/ml) did not produce detectable levels of nitrite.
We examined the effect of fluvastatin, a statin with lipo-
philic properties, on nitrite accumulation in LPS- and LPS/
IFN-stimulated VSMC (Fig. 1A). Fluvastatin potentiated
both LPS- and LPS/IFN-stimulated nitrite production in a
concentration-dependent manner when added to VSMC
before LPS. As shown in Fig. 1A, fluvastatin caused a
50% increase in nitrite production over that achieved with
LPS alone at a concentration of 5 AM. Fig. 1B shows the
time course of changes in nitrite accumulation within the
culture medium following exposure to LPS/IFN and fluvas-Fig. 4. (A) Immunoblot showing the effect of fluvastatin on the activity of Rho A
AM). A pull-down assay using GST-Rhotekin bound to glutathione-Sepharose 4B
Western blotting. Similar results were obtained in three independent experiments.
production in rat VSMC. Cells were treated with LPS/IFN in the presence of Y-2
medium was measured. Effect of Y-27632 (10 AM) on the fluvastatin (25 AM) effec
and Lat B act was examined in the regulation of NO synthesis in LPS-treated VSM
25 (closed squares) AM. Data are presented as the meanF S.E. (n = 6). *P < 0.05
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Atatin. A lag phase of 6–8 h preceded the induction, followed
by a progressive increase in nitrite synthesis for at least 24 h.
The amount of nitrite that accumulated 24 h after stimula-
tion was 28.3F 0.6 AM. Fluvastatin produced a significant
increase in cumulative nitrite production in VSMC (see Fig.
1B). The amount of nitrite that accumulated in the presence
of fluvastatin (25 AM) 24 h after stimulation with LPS/IFN
was 54.6F 1.9 AM.
We investigated whether or not fluvastatin impacts iNOS
gene and protein expression by Northern and Western
blotting. While iNOS mRNA levels approached the detec-
tion limit in unstimulated VSMC, substantial induction of
iNOS by LPS/IFN was observed (Fig. 2), which was further. VSMC were cultured for 6 h in the presence or absence of fluvastatin (25
beads was performed. The amount of GTP-bound Rho Awas quantitated by
(B) Effect of various concentrations of Y-27632 on LPS/IFN-induced NO
7632 (0.1–10 AM) for 24 h, after which nitrite accumulation in the culture
t was also examined in LPS-stimulated NO production. (C) How fluvastatin
C. Fluvasatin concentrations were 0 (closed circles), 5 (closed triangles), and
and **P < 0.01 compared with control values.
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Aenhanced by fluvastatin. The lower panel of Fig. 2 shows
substantial induction of iNOS protein, which was present at
very low levels in unstimulated cells, by LPS/IFN. This was
also enhanced by fluvastatin.
To identify which product of the HMG-CoA reductase
reaction is responsible for the effect of fluvastatin, meval-
onate, FPP, and GGPP were each added separately to
VSMC stimulated with LPS/IFN in the presence of fluvas-
tatin. Mevalonate is a cholesterol precursor, and FPP and
GGPP are involved in the farnesylation and geranylgerany-
lation of proteins, respectively. Mevalonate (0.1 mM) com-
pletely reversed the fluvastatin-induced increase in nitrite
production (Fig. 3). Similarly, GGPP (10 AM) completely
reversed the fluvastatin-induced increase in nitrite produc-
tion, while FPP (10 AM) did not block this effect of the
statins (Fig. 3). Mevalonate, FPP, and GGPP alone did not
affect basal or LPS/IFN-induced nitrite production (data not
shown).
To clarify the association between fluvastatin and Rho
activation, we determined the activity of Rho A by a pull-
down assay after 6 h of culture. Fluvastatin markedly
decreased the levels of GTP-bound Rho A (Fig. 4A),
providing direct evidence that statins down-regulate the
activity of Rho in VSMC. Among the effectors of Rho,
we examined the role of Rho-kinase in the synthesis of NO.
A Rho kinase inhibitor, Y-27632, dose-dependently in-
creased LPS/IFN-induced NO production in VSMC. Y-
27632 also enhanced the effect of fluvastatin in LPS-
stimulated VSMC (Fig. 4B). We further examined how
Lat B and fluvastatin act in the induction of NO synthesis
in response to LPS. Lat B enhanced LPS-induced NO
production in a concentration-dependent manner both inFig. 5. Fluvastatin inhibits F-actin polymerization. VSMC were either untreated
unstimulated or stimulated with LPS (30 Ag/ml) and IFN (10 ng/ml) for 1 h. Cells
and stained with 165 nM NBD-phallacidin. Stained F-actin was imaged using a
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increasing effect of fluvastatin was reversely lessened at
higher concentration of Lat B (1 AM) (Fig. 4C).
To test whether the enhancement of LPS/IFN-induced
iNOS expression by fluvastatin was associated with an
inhibition of actin polymerization in VSMC, we stained F-
actin with NBD-phallacidin, a fluorescent toxin that binds
to F-actin. Fig. 5 shows that fluvastatin by itself, or
together with LPS/IFN, caused a significant disruption to
F-actin filaments with loss of stress fiber formation, where-
as 1 h of LPS/IFN treatment alone had little effect on F-
actin structure.4. Discussion
The present findings demonstrate that statins enhance the
induction of NO synthesis by LPS in VSMC, confirming the
results of a previous report and broadening our understand-
ing of the mechanisms underlying the effects of statins. We
previously showed that statins enhance immunostimulant-
induced NO production by increasing iNOS gene expression
at the transcriptional level via an NF-nB-independent path-
way [18]. We recently demonstrated that disruption of F-
actin formation dramatically potentiates LPS-induced
increases in iNOS mRNA and protein expression [19]. We
think there must be a strong link between these findings.
Rho activation requires gerenylgeranylation from a pool
of unprocessed Rho, as well as a GDP/GTP exchange and
translocation to the cell membrane. Our pull-down assay
demonstrated that statins decrease the levels of GTP-bound
Rho A in VSMC. This is direct evidence that statins
CT
EDor treated with 25 AM fluvastatin for 6 h, after which they were either
were then fixed with a 3.7% formaldehyde solution, washed with acetone,
Nikon epifluorescent microscope.
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suggesting that statins up-regulate the synthesis of NO via
inactivation of Rho.
There are a number of Rho targeting molecules, includ-
ing Rho-kinase/ROK/ROCKII, ROK/ROCKI, protein ki-
nase N, rhophilin, rhotekin, citron and p140mDia [22,23].
Among these effectors, Rho-kinase is involved in smooth
muscle contraction, stress fiber formation, focal adhesion
formation, neurite retraction and cytokinesis. In the present
study, Y-27632 enhanced NO synthesis in VSMC, suggest-
ing that Rho-kinase is also responsible for regulation of NO
synthesis. Fluvasatin modulated the effect of Lat B in the
induction of NO, indicating the common mechanism of the
enhancement of NO production.
The present study shows that inhibition of Rho/Rho-
kinase signalling by statins up-regulates the synthesis of NO
in VSMC. Our data also show that statins cause significant
disruption to F-actin filaments with a loss of stress fiber
formation, which might be associated with enhanced NO
synthesis in VSMC. Thus, statins seem to inhibit Rho/Rho-
kinase signalling, thereby causing disruption of the actin
cytoskeleton and increasing the production of NO in
VSMC.
In conclusion, statin blocks Rho/Rho-kinase signalling
and causes disruption of the actin cytoskeleton, which may
enhance LPS-mediated induction of NO synthesis in VSMC.
Thus, this effect, which occurred nearly at concentrations
that are reached after administration in conventional doses
[24,25], may represent an important mechanism by which
these drugs provide protection against atherosclerosis. A
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